JP2025504768A - 神経疾患の予防または治療のためのイオン液体ベースの製剤 - Google Patents

神経疾患の予防または治療のためのイオン液体ベースの製剤 Download PDF

Info

Publication number
JP2025504768A
JP2025504768A JP2024539747A JP2024539747A JP2025504768A JP 2025504768 A JP2025504768 A JP 2025504768A JP 2024539747 A JP2024539747 A JP 2024539747A JP 2024539747 A JP2024539747 A JP 2024539747A JP 2025504768 A JP2025504768 A JP 2025504768A
Authority
JP
Japan
Prior art keywords
inh
chol
ionic liquid
disease
liquid according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504768A5 (https=
Inventor
グアダルーペ フレイレ マルティンス マーラ
カタリーナ アルメイダ ソウサ アナ
シャルマ ムケシュ
マヌエル コスタ アラウージョ ペレイラ コウチーニョ ジュアン
クララ ブラズ クリストヴォ アナ
ペレイラ ジナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Aveiro
Original Assignee
Universidade de Aveiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Aveiro filed Critical Universidade de Aveiro
Publication of JP2025504768A publication Critical patent/JP2025504768A/ja
Publication of JP2025504768A5 publication Critical patent/JP2025504768A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024539747A 2022-01-26 2023-01-26 神経疾患の予防または治療のためのイオン液体ベースの製剤 Pending JP2025504768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT117761 2022-01-26
PT11776122 2022-01-26
PCT/IB2023/050671 WO2023144742A1 (en) 2022-01-26 2023-01-26 Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

Publications (2)

Publication Number Publication Date
JP2025504768A true JP2025504768A (ja) 2025-02-19
JP2025504768A5 JP2025504768A5 (https=) 2025-12-03

Family

ID=85936842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539747A Pending JP2025504768A (ja) 2022-01-26 2023-01-26 神経疾患の予防または治療のためのイオン液体ベースの製剤

Country Status (6)

Country Link
US (1) US12514845B2 (https=)
EP (1) EP4469044B1 (https=)
JP (1) JP2025504768A (https=)
CN (1) CN118524836B (https=)
CA (1) CA3242202A1 (https=)
WO (1) WO2023144742A1 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012201058A1 (en) 2003-08-29 2012-03-15 President And Fellows Of Harvard College Inhibitors of cellular necrosis
KR20080051246A (ko) 2006-12-05 2008-06-11 (주)에스에이치제약 뇌신경계 질환의 예방 또는 치료용 및 ｎａｄｐｈ 산화효소활성억제용 약학적 조성물
WO2010078258A1 (en) 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Compounds comprising two or more biologically functional ions and method of treating parkinson's disease
EP2554163A4 (en) 2010-03-26 2013-07-17 Univ Hokkaido Nat Univ Corp THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
KR101411838B1 (ko) 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
US8673956B2 (en) 2011-12-02 2014-03-18 Board Of Trustees Of The University Of Alabama Imido-acid salts and methods of use
CN103330708B (zh) 2013-07-23 2014-11-26 苏州大学 5-(3’，5’-二甲氧基苯甲撑基)-2-硫代-咪唑-4-酮在制备治疗脑血管疾病的药物中的应用
WO2015129527A1 (ja) 2014-02-27 2015-09-03 株式会社メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
EP3129102B1 (en) 2014-04-07 2025-06-18 The United States of America, as represented by The Secretary, Department of Health and Human Services Iodonium analogs as inhibitors of nadph oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof
JP2015227329A (ja) 2014-05-09 2015-12-17 サントリーホールディングス株式会社 メトキシフラボンを含むＮＯＸ阻害剤及びＮＦκＢ阻害剤
WO2018129421A1 (en) 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease
WO2019023448A1 (en) 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR20200022193A (ko) 2018-08-22 2020-03-03 한림대학교 산학협력단 결핵성 흉막 섬유증 예방 또는 치료용 약학 조성물
WO2020205937A1 (en) 2019-04-01 2020-10-08 Emory University Hyaluronic acid nanoparticles comprising nadph oxidases inhibitors and uses in treating cancer
CN111138376A (zh) 2019-12-24 2020-05-12 中山大学 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用
US12552779B2 (en) * 2020-07-10 2026-02-17 Duksung Women's University Industry-Academic Cooperation Foundation 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-on and derivative thereof, preparation method therefor, and composition comprising same for preventing, alleviating or treating neurodegenerative diseases

Also Published As

Publication number Publication date
EP4469044B1 (en) 2026-04-08
CN118524836B (zh) 2026-03-27
WO2023144742A1 (en) 2023-08-03
CA3242202A1 (en) 2023-08-03
EP4469044A1 (en) 2024-12-04
CN118524836A (zh) 2024-08-20
US20240415815A1 (en) 2024-12-19
US12514845B2 (en) 2026-01-06

Similar Documents

Publication Publication Date Title
US10143671B2 (en) Solid solution compositions and use in chronic inflammation
EP2925367B1 (en) Solid solution compositions and use in chronic inflammation
KR102011641B1 (ko) 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
EP4243797B1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
US20230285303A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
US10835490B2 (en) Solid solution compositions and use in chronic inflammation
US9522128B2 (en) Use of cilastatin to reduce the nephrotoxicity of different compounds
CN115317512A (zh) 普鲁士蓝及其类似物在制备预防、延缓或治疗细胞焦亡相关疾病药物中的应用
TWI472519B (zh) 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能
US12514845B2 (en) Ionic-liquid-based formulations for the prevention or treatment of neurological diseases
US20130225545A1 (en) Porphyrin treatment of neurodegenerative diseases
US20150191430A1 (en) Conjugates of huperzine and analogs thereof
HK40110065A (zh) 用於预防或治疗神经系统疾病的基於离子液体的调配物
US20240066038A1 (en) Wnt modulators to treat central nervous system injuries
US20230098649A1 (en) Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof
HK40058590A (en) Solid solution compositions and use in chronic inflammation
HK40018887B (en) Solid solution compositions and use in chronic inflammation
HK40018887A (en) Solid solution compositions and use in chronic inflammation
EA043008B1 (ru) Комбинации эдаравона для лечения ишемических повреждений мозга
هبه نعيم خميس غريب Synthesis and Characterization of Designed Tranexamic Acid and Paracetamol Prodrugs
HK1216004B (en) Solid solution compositions and use in chronic inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251125